rdf:type |
|
lifeskim:mentions |
umls-concept:C0001455,
umls-concept:C0008972,
umls-concept:C0042036,
umls-concept:C0042037,
umls-concept:C0043047,
umls-concept:C0085413,
umls-concept:C0086741,
umls-concept:C0205178,
umls-concept:C0205191,
umls-concept:C0220825,
umls-concept:C0392747,
umls-concept:C0443172,
umls-concept:C0473169,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1708715,
umls-concept:C2346689,
umls-concept:C2911692
|
pubmed:issue |
4
|
pubmed:dateCreated |
2010-4-8
|
pubmed:abstractText |
Autosomal dominant polycystic kidney disease (ADPKD) leads to kidney failure in half of those affected. Increased levels of adenosine 3':5'-cyclic monophosphate (cAMP) play a critical role in disease progression in animal models. Water loading, by suppressing arginine vasopressin (AVP)-stimulated cAMP production, is a proposed therapy for ADPKD.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-10760082,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-11286938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-11684564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-12753285,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-14711914,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-14991049,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-15203099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-15327388,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-15728778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-1614046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-16707749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-16807403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-18032793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-18263895,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-19342421,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-19443627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-224712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-2709672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-3740301,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-7908078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20167686-9370187
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1555-905X
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
693-7
|
pubmed:dateRevised |
2011-7-27
|
pubmed:meshHeading |
pubmed-meshheading:20167686-Adult,
pubmed-meshheading:20167686-Arginine Vasopressin,
pubmed-meshheading:20167686-Biological Markers,
pubmed-meshheading:20167686-Cyclic AMP,
pubmed-meshheading:20167686-Disease Progression,
pubmed-meshheading:20167686-Down-Regulation,
pubmed-meshheading:20167686-Drinking,
pubmed-meshheading:20167686-Female,
pubmed-meshheading:20167686-Fluid Therapy,
pubmed-meshheading:20167686-Humans,
pubmed-meshheading:20167686-Male,
pubmed-meshheading:20167686-Osmolar Concentration,
pubmed-meshheading:20167686-Pilot Projects,
pubmed-meshheading:20167686-Polycystic Kidney, Autosomal Dominant,
pubmed-meshheading:20167686-Time Factors,
pubmed-meshheading:20167686-Treatment Outcome,
pubmed-meshheading:20167686-Water-Electrolyte Balance
|
pubmed:year |
2010
|
pubmed:articleTitle |
A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.
|
pubmed:affiliation |
Department of Medicine, Division of Nephrology, 550 First Avenue, New York, NY 10016, USA. irina.barash@nyumc.org
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial
|